These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9890717)

  • 1. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0.
    Erhardtsen E; Nony P; Dechavanne M; Ffrench P; Boissel JP; Hedner U
    Blood Coagul Fibrinolysis; 1998 Nov; 9(8):741-8. PubMed ID: 9890717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.
    Skolnick BE; Mathews DR; Khutoryansky NM; Pusateri AE; Carr ME
    Blood; 2010 Aug; 116(5):693-701. PubMed ID: 20385794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates.
    Sadeghi N; Iacobelli M; Vaziri B; Kahn D; Hoppensteadt D; Guler N; Fareed J
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):211-220. PubMed ID: 27553841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
    Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
    Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant FVIIa in the treatment of warfarin bleeding.
    Berntorp E
    Semin Thromb Hemost; 2000; 26(4):433-5. PubMed ID: 11092220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
    Dickneite G
    Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?
    Voils SA; Baird B
    Thromb Res; 2012 Dec; 130(6):833-40. PubMed ID: 23137921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage.
    Sarode R; Matevosyan K; Bhagat R; Rutherford C; Madden C; Beshay JE
    J Neurosurg; 2012 Mar; 116(3):491-7. PubMed ID: 22175718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; Haas FJ; Levi M; Sturk A
    Thromb Haemost; 2007 Oct; 98(4):738-46. PubMed ID: 17938796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
    Tanaka KA; Szlam F; Dickneite G; Levy JH
    Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans.
    Hollenstein U; Homoncik M; Knöbl P; Pernerstorfer T; Graggaber J; Eichler HG; Handler S; Jilma B
    Clin Pharmacol Ther; 2002 May; 71(5):368-74. PubMed ID: 12011822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing.
    Walenga JM; Drenth AF; Mayuga M; Hoppensteadt DA; Prechel M; Harder S; Watanabe H; Osakabe M; Breddin HK
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):325-31. PubMed ID: 18586683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal.
    Kinard TN; Sarode R
    Expert Rev Cardiovasc Ther; 2014 Apr; 12(4):417-27. PubMed ID: 24650310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin.
    Dager WE; King JH; Regalia RC; Williamson D; Gosselin RC; White RH; Tharratt RS; Albertson TE
    Pharmacotherapy; 2006 Aug; 26(8):1091-8. PubMed ID: 16863486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of vitamin K in patients on anticoagulant therapy: a practical guide.
    Hanslik T; Prinseau J
    Am J Cardiovasc Drugs; 2004; 4(1):43-55. PubMed ID: 14967065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.
    Friederich PW; Levi M; Bauer KA; Vlasuk GP; Rote WE; Breederveld D; Keller T; Spataro M; Barzegar S; Büller HR
    Circulation; 2001 May; 103(21):2555-9. PubMed ID: 11382723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Fresh-Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study.
    Kwon JO; MacLaren R
    Pharmacotherapy; 2016 Oct; 36(10):1047-1054. PubMed ID: 27547916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.